Financhill
Sell
17

EQ Quote, Financials, Valuation and Earnings

Last price:
$0.59
Seasonality move :
35.05%
Day range:
$0.58 - $0.61
52-week range:
$0.56 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.46x
P/B ratio:
0.90x
Volume:
100.6K
Avg. volume:
126.5K
1-year change:
-18.92%
Market cap:
$20.9M
Revenue:
$36.1M
EPS (TTM):
-$0.14

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EQ
Equillium
$11.6M $0.14 -100% -276.19% --
ATEC
Alphatec Holdings
$147.2M -$0.11 23.49% -83.35% $16.88
MDGL
Madrigal Pharmaceuticals
$34.4M -$6.91 -- -23.06% --
MTNB
Matinas BioPharma Holdings
-- -$1.06 -100% -45.83% --
SPRO
Spero Therapeutics
$7.7M -$0.36 -100% -505.55% $5.00
TNON
Tenon Medical
$1.3M -$6.16 11.51% -60.9% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EQ
Equillium
$0.59 -- $20.9M -- $0.00 0% 0.46x
ATEC
Alphatec Holdings
$9.34 $16.88 $1.3B -- $0.00 0% 2.29x
MDGL
Madrigal Pharmaceuticals
$308.71 -- $6.7B -- $0.00 0% --
MTNB
Matinas BioPharma Holdings
$0.55 -- $2.8M -- $0.00 0% 0.60x
SPRO
Spero Therapeutics
$0.96 $5.00 $52.3M 12.00x $0.00 0% 0.58x
TNON
Tenon Medical
$1.85 -- $5.8M -- $0.00 0% 0.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EQ
Equillium
-- 8.502 -- 2.90x
ATEC
Alphatec Holdings
100.26% -0.009 66.79% 1.02x
MDGL
Madrigal Pharmaceuticals
13.09% 3.388 2.53% 5.79x
MTNB
Matinas BioPharma Holdings
-- 6.772 -- --
SPRO
Spero Therapeutics
-- 2.060 -- 2.64x
TNON
Tenon Medical
-- -0.884 -- 3.16x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EQ
Equillium
-- -$679K -20.35% -20.35% -0.06% -$7.7M
ATEC
Alphatec Holdings
$102.7M -$30.7M -33.31% -1019.24% -21.95% -$25.2M
MDGL
Madrigal Pharmaceuticals
$60M -$116.3M -74.25% -89.04% -166.12% -$67.8M
MTNB
Matinas BioPharma Holdings
-- -$4.4M -- -- -- -$3.5M
SPRO
Spero Therapeutics
-- -$18.6M 4.36% 4.36% -237.79% $12.8M
TNON
Tenon Medical
$418K -$3.2M -400.82% -430.31% -358.96% -$2.4M

Equillium vs. Competitors

  • Which has Higher Returns EQ or ATEC?

    Alphatec Holdings has a net margin of -0.06% compared to Equillium's net margin of -26.29%. Equillium's return on equity of -20.35% beat Alphatec Holdings's return on equity of -1019.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    ATEC
    Alphatec Holdings
    68.16% -$0.28 $526.4M
  • What do Analysts Say About EQ or ATEC?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Alphatec Holdings has an analysts' consensus of $16.88 which suggests that it could grow by 80.68%. Given that Equillium has higher upside potential than Alphatec Holdings, analysts believe Equillium is more attractive than Alphatec Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    ATEC
    Alphatec Holdings
    6 1 0
  • Is EQ or ATEC More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Alphatec Holdings has a beta of 1.386, suggesting its more volatile than the S&P 500 by 38.566%.

  • Which is a Better Dividend Stock EQ or ATEC?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Alphatec Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or ATEC?

    Equillium quarterly revenues are $12.2M, which are smaller than Alphatec Holdings quarterly revenues of $150.7M. Equillium's net income of -$7K is higher than Alphatec Holdings's net income of -$39.6M. Notably, Equillium's price-to-earnings ratio is -- while Alphatec Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 2.29x for Alphatec Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    ATEC
    Alphatec Holdings
    2.29x -- $150.7M -$39.6M
  • Which has Higher Returns EQ or MDGL?

    Madrigal Pharmaceuticals has a net margin of -0.06% compared to Equillium's net margin of -172.04%. Equillium's return on equity of -20.35% beat Madrigal Pharmaceuticals's return on equity of -89.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    MDGL
    Madrigal Pharmaceuticals
    96.54% -$4.92 $894.2M
  • What do Analysts Say About EQ or MDGL?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 20.83%. Given that Equillium has higher upside potential than Madrigal Pharmaceuticals, analysts believe Equillium is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    MDGL
    Madrigal Pharmaceuticals
    0 0 0
  • Is EQ or MDGL More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

  • Which is a Better Dividend Stock EQ or MDGL?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or MDGL?

    Equillium quarterly revenues are $12.2M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Equillium's net income of -$7K is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Equillium's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    MDGL
    Madrigal Pharmaceuticals
    -- -- $62.2M -$107M
  • Which has Higher Returns EQ or MTNB?

    Matinas BioPharma Holdings has a net margin of -0.06% compared to Equillium's net margin of --. Equillium's return on equity of -20.35% beat Matinas BioPharma Holdings's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    MTNB
    Matinas BioPharma Holdings
    -- -$0.85 --
  • What do Analysts Say About EQ or MTNB?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 5404.59%. Given that Matinas BioPharma Holdings has higher upside potential than Equillium, analysts believe Matinas BioPharma Holdings is more attractive than Equillium.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    MTNB
    Matinas BioPharma Holdings
    0 0 0
  • Is EQ or MTNB More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.222%.

  • Which is a Better Dividend Stock EQ or MTNB?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or MTNB?

    Equillium quarterly revenues are $12.2M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. Equillium's net income of -$7K is higher than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Equillium's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.60x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    MTNB
    Matinas BioPharma Holdings
    0.60x -- -- -$4.3M
  • Which has Higher Returns EQ or SPRO?

    Spero Therapeutics has a net margin of -0.06% compared to Equillium's net margin of -219.3%. Equillium's return on equity of -20.35% beat Spero Therapeutics's return on equity of 4.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    SPRO
    Spero Therapeutics
    -- -$0.32 $65.5M
  • What do Analysts Say About EQ or SPRO?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 421%. Given that Equillium has higher upside potential than Spero Therapeutics, analysts believe Equillium is more attractive than Spero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    SPRO
    Spero Therapeutics
    1 2 0
  • Is EQ or SPRO More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.892%.

  • Which is a Better Dividend Stock EQ or SPRO?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or SPRO?

    Equillium quarterly revenues are $12.2M, which are larger than Spero Therapeutics quarterly revenues of $7.8M. Equillium's net income of -$7K is higher than Spero Therapeutics's net income of -$17.1M. Notably, Equillium's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.58x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    SPRO
    Spero Therapeutics
    0.58x 12.00x $7.8M -$17.1M
  • Which has Higher Returns EQ or TNON?

    Tenon Medical has a net margin of -0.06% compared to Equillium's net margin of -358.96%. Equillium's return on equity of -20.35% beat Tenon Medical's return on equity of -430.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    EQ
    Equillium
    -- -$0.00 $23.2M
    TNON
    Tenon Medical
    47.13% -$29.04 $8.2M
  • What do Analysts Say About EQ or TNON?

    Equillium has a consensus price target of --, signalling upside risk potential of 464.88%. On the other hand Tenon Medical has an analysts' consensus of -- which suggests that it could grow by 332.43%. Given that Equillium has higher upside potential than Tenon Medical, analysts believe Equillium is more attractive than Tenon Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    EQ
    Equillium
    3 0 0
    TNON
    Tenon Medical
    0 0 0
  • Is EQ or TNON More Risky?

    Equillium has a beta of 1.782, which suggesting that the stock is 78.182% more volatile than S&P 500. In comparison Tenon Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock EQ or TNON?

    Equillium has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Equillium pays -- of its earnings as a dividend. Tenon Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EQ or TNON?

    Equillium quarterly revenues are $12.2M, which are larger than Tenon Medical quarterly revenues of $887K. Equillium's net income of -$7K is higher than Tenon Medical's net income of -$3.2M. Notably, Equillium's price-to-earnings ratio is -- while Tenon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Equillium is 0.46x versus 0.18x for Tenon Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EQ
    Equillium
    0.46x -- $12.2M -$7K
    TNON
    Tenon Medical
    0.18x -- $887K -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 2.15% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.55% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock